TNF-like ligand 1 A (TL1A) and death receptor 3 (DR3) are a ligand-receptor pair involved in the pathogenesis of inflammatory bowel disease. Group 3 innate lymphoid cells (ILC3s) regulate intestinal immunity and highly express DR3. Here, we report that activation of DR3 signaling by an agonistic anti-DR3 antibody increases GM-CSF production from ILC3s through the p38 MAPK pathway. GM-CSF causes accumulation of eosinophils, neutrophils and CD11b + CD11c + myeloid cells, resulting in loss of ILC3s from the intestine in an IL-23dependent manner and exacerbating colitis. Blockade of GM-CSF or IL-23 reverses anti-DR3 antibody-driven ILC3 loss, whereas overexpression of IL-23 induces loss of ILC3s in the absence of GM-CSF. Neutralization of TL1A by soluble DR3 ameliorates both DSS and anti-CD40 antibody-induced colitis. Moreover, ILC3s are required for the deleterious effect of anti-DR3 antibodies on innate colitis. These findings clarify the process and consequences of DR3 signaling-induced intestinal inflammation through regulation of ILC3s.
T NF-like ligand 1A (TL1A) and death receptor 3 (DR3) are a TNF family ligand-receptor pair that is expressed in both mice and humans and has important functions in inflammatory diseases 1 . TL1A is mainly expressed by antigen presenting cells upon stimulation with Toll-like receptor (TLR) ligands or immune complexes 2 , whereas DR3 is broadly expressed by lymphocytes, including CD4 + T cells, CD8 + T cells, invariant natural killer T (iNKT) cells, and innate lymphoid cells (ILCs) 1, 3 . TL1A/DR3 signaling has been reported to promote the proliferation and cytokine production by subsets of T effector cells and facilitate the progress of inflammatory diseases, such as experimental autoimmune encephalomyelitis (EAE) and allergic pulmonary diseases 1, 2, 4, 5 .
In addition to the pro-inflammatory aspect, activation of TL1A/DR3 signaling also has an immunosuppressive role through expansion of T-regulatory cells (Tregs) 4 . This effect can be achieved by administration of an agonistic antibody against DR3 or TL1A-Ig, which is considered to be a therapeutic strategy for autoimmune diseases 6, 7 . Activation of DR3 signaling has shown treatment efficacy on multiple inflammatory diseases, such as EAE, lung inflammation, and graft-versus-host diseases (GVHD) 6, [8] [9] [10] , therefore sometimes leading to contradictory conclusions on the effect of TL1A/DR3 with TL1A/DR3-blockade studies. The impact of TL1A/DR3 signaling on inflammation may be determined by environmental factors.
The dual role of TL1A/DR3 signaling in inflammation is also manifested in inflammatory bowel disease (IBD). Mice lacking DR3 or TL1A are susceptible to dextran sulfate sodium (DSS)induced colitis accompanied by reduced number of Tregs 11 . However, TL1A/DR3 signaling has been predominantly proved by numerous studies to be detrimental in IBD [12] [13] [14] . Polymorphisms of Tnfsf15 (encoding TL1A) has been linked to susceptibility to Crohn's disease (CD) by genome-wide association studies in humans 15, 16 . Expression of TL1A is enhanced in inflamed tissues of IBD patients 17 . Genetically forced expression of TL1A causes spontaneous small intestinal inflammation featured by overt type 2 innate immune responses 3, 18 . Furthermore, neutralization of TL1A in chronic DSS-induced colitis ameliorates the disease, probably by limiting Th1 and Th17 responses 19 .
Group 3 innate lymphoid cells (ILC3s) and ILC2s are subsets of ILCs that lack specific T-and B-cell receptors 20 . Abundant numbers of both ILC3s and ILC2s are localized in the intestine of mice, and play crucial roles in intestinal inflammation 21, 22 . Notably, DR3 has been found to be highly expressed by all subsets of ILCs 3 . TL1A transgenic mice manifest spontaneous small intestinal inflammation mediated by IL-5 and IL-13 secreted from ILC2s independently of T cells, indicating ILC2s being key targets for TL1A-driven inflammation 3, 18 . In the intestine, TL1A is reported to be mainly derived from CX 3 CR1 + mononuclear phagocytes 23 . TL1A has been shown to promote GM-CSF and IL-22 expression from ILC3s in synergy with IL-1β and IL-23, which contributes to the immune defensive function of CX 3 CR1 + mononuclear phagocytes in intestinal infection 23 . Whether ILC3s participate in TL1A-mediated intestinal inflammation is unclear.
Under the steady-state of the intestine, ILC3s have been found to be a primary source for GM-CSF that is involved in intestinal inflammation through various mechanisms 24 . GM-CSF supports the induction of intestinal Tregs through accumulation of TGF-βproducing CD11b + CD103 + dendritic cells 24 . On the other hand, GM-CSF can be highly pathogenic in colitis by activating eosinophils and enhancing cytokine production from eosinophils 25 . Another report has shown that blockade of GM-CSF ameliorates α-CD40-induced innate colitis and orchestrates mobilization of ILC3s during colitis 26 . Notably, reduced number of ILC3s in α-CD40-induced innate colitis in mouse models is compatible with the observation that fraction of ILC3s is reduced in inflamed intestine of CD patients compared with non-inflamed controls [26] [27] [28] . Although the conversion of ILC3s to ILC1s has been demonstrated to be a reason for this phenomenon, other molecular mechanisms underlying the dynamics of ILC3s in IBDs may exist.
In this study, we report that α-DR3 exacerbates colitis through stimulation of ILC3s, while finally induces loss of ILC3s in the large intestine. Agonistic antibody targeting DR3 (α-DR3) robustly drives loss of ILC3s, which is accompanied by infiltration of pro-inflammatory myeloid cells. Mechanistically, α-DR3 promotes GM-CSF production from ILC3s, which leads to the accumulation of eosinophils, neutrophils, and IL-23-producing CD11b + CD11c + cells. Blockade of either GM-CSF or IL-23 reverses α-DR3-driven ILC3 loss, whereas IL-23 eliminates ILC3s from the large intestine in the absence of GM-CSF. α-DR3 exacerbates DSS-induced colitis independently of the adaptive immune system. Strikingly, the exacerbation of DSS-induced innate colitis by α-DR3 is not observed in the absence of ILC3s, suggesting a critical role of ILC3s in initiating the inflammatory storm. Transcriptome analysis reveals upregulation of MAPK cascade-related genes in ILC3s upon α-DR3 treatment. We have further proved that p38 signaling is essential for GM-CSF production by ILC3s induced by TL1A/DR3 signaling in both mice and humans. Our finding uncovers the molecular mechanism underlying the intestinal pathology mediated through TL1A/ DR3 signaling in ILC3s.
Results
α-DR3 induces reduction of ILC3 numbers in the large intestine. DR3 has been found to be highly expressed by subsets of ILCs in the intestine 3 . To examine the effect of DR3 signaling on intestinal ILCs, we treated mice with an α-DR3 agonistic antibody (4C12), which has been shown to boost Tregs and may be implicated in treatment of autoimmune diseases. Tregs were efficiently expanded in the large intestine by two injections of 2.5 µg of α-DR3 every other day ( Supplementary Fig. 1A, B ). In addition, we observed a significantly decreased proportion of NKp46 -ILC3s among the Lineage -(Lin -) cells in LPLs (lamina propria lymphocytes) of the large intestine ( Fig. 1a 29 . There was also a mild trend toward a reduction in percentage of NCR + ILC3s among Lincells ( Fig. 1a , c), while percentages of ILC2s and ILC1s in Lincells were not affected by α-DR3 treatment ( Fig. 1a, d ). The total number of ILC3s was also reduced (Fig. 1e ). The mRNA expression of IL-22 in large intestinal LPLs was decreased upon α-DR3 treatment probably due to loss of ILC3s, which are the major sources of IL-22 ( Fig. 1f) 30, 31 .
To identify if α-DR3-driven loss of ILC3s was dependent on the adaptive immune system, we administered α-DR3 to Rag1 -/mice which lack T and B cells. The expression of DR3 was similar in subsets of ILCs from Rag1 -/mice compared with wild-type mice ( Supplementary Fig. 1D ). Strikingly, the total number of ILC3s, as well as proportions of NCR + ILC3s and NKp46 -ILC3s among Lincells, was dramatically decreased upon α-DR3 treatment ( Fig. 1g -i; Supplementary Fig. 1E ). Consistently, absolute number of IL-22-producing ILC3s was decreased in α-DR3-treated mice ( Fig. 1j ). Similar effect on ILC3s was achieved by overexpression of TL1A in Rag1 -/mice using hydrodynamic injection ( Fig. 1k -n). Using Rorc gfp/+ Rag1 -/mice with a GFP reporter to indicate the expression of RORγt 32 , we analyzed the distribution of ILC3s (GFP + cells) in the large intestine by immunofluorescence staining of GFP. In α-DR3-treated mice, we observed a reduction in the number of cryptopatches where ILC3s are typically localized (Fig. 1o, p) 33 . Although the total number of ILC3s per analyzed cryptopatch was not affected by α-DR3 treatment (Fig. 1o, q) , the structure of cryptopatches was looser, leading to reduced density of ILC3s in individual cryptopatches ( Fig. 1o, r) . The above data suggest α-DR3induced loss of ILC3s is independent of the adaptive immune system. Control IgG had no observed effect on loss of ILC3s compared with PBS ( Supplementary Fig. 1F -K), we thus utilized PBS as a control in the following experiments.
α-DR3-induced ILC3 loss is not a result of cell apoptosis in situ. The percentage of Ki67 + ILC3s was enhanced upon treatment with α-DR3 ( Fig. 2a, b ), suggesting there is no defect in proliferation of ILC3s upon α-DR3 treatment 34 . Activation of DR3 has been reported to induce cell apoptosis 35 . However, level of cleaved caspase 3, an indicator of cell apoptosis 36 Fig. 2A ). Furthermore, treatment of mice with zVAD-FMK, a pancaspase inhibitor, failed to block the reduction of ILC3s induced by α-DR3 ( Supplementary Fig. 2B , C). The above data indicate that α-DR3-driven loss of ILC3s is not due to cell apoptosis. The conversion of ILC3s to ILC1s can occur under the inflammatory status, and has been suggested to contribute to the proportional change of ILC1 and NKp44 + ILC3 in CD patients 37, 38 . To determine if α-DR3-induced loss of ILC3s was due to a fate conversion of ILC3s, we injected α-DR3 to Rag1 -/-Rorc-creRosa26 stop-YFP mice, which could be used to track the fate of ILC3s by examining the expression of YFP (representing both current and historic ILC3s) and RORγt (representing current ILC3s) ( Fig. 2c ; Supplementary Fig. 2D ) 39 . A reduction of both Lin -YFP + RORγtcells (exILC3s) and Lin -YFP + RORγt + cells (current ILC3s) was observed in α-DR3-treated mice ( Fig. 2c ; Supplementary Fig. 2D ). The level of exILC3s in the α-DR3treated mice did not compensate for the loss of current ILC3s ( Fig. 2c ; Supplementary Fig. 2D ). Consistently, no compensatory increase in numbers of ILC1s, ILC2s, or Linnon-ILCs was found upon α-DR3 treatment, although there was a trend toward a proportionally increased level of ILC2s among Lincells, probably due to primary loss of ILC3s ( Supplementary Fig. 2E , F). The above data imply that fate conversion is not a key mechanism for the reduction of ILC3s induced by α-DR3 at least in situ.
GM-CSF induced by α-DR3 is critical for ILC3 loss. Mobilization of ILC3s induced by GM-CSF has been found to cause loss of ILC3s in innate colitis 26 . A previous study has shown that TL1A promoted GM-CSF production by ILC3s in vitro 23 . When Rag1 -/mice were treated with α-DR3, GM-CSF production by ILC3s was significantly enhanced 24 h after α-DR3 treatment, before loss of ILC3s was observed ( Fig. 2d, e ). Strikingly, blockade of GM-CSF with a neutralizing antibody efficiently prevented loss of ILC3s that was triggered by α-DR3 ( Fig. 2f -h). The above data suggest that GM-CSF induced by α-DR3 is critical for loss of ILC3s in the intestine. GM-CSF could originate from various types of immune cells during inflammation 24, 40, 41 . We thus questioned if paracrine source of GM-CSF could drive loss of ILC3s induced by α-DR3. We constructed bone marrow chimeric mouse on ILC-deficient Rag2 -/-Il2rg -/recipients by mixing donor bone marrows from Thy1.1 + wild-type and Thy1.2 + Csf2 -/mice at a 1:1 ratio ( Fig. 2i ). In the above system, environmental GM-CSF could be supplemented by wild-type bone marrows. After treatment with α-DR3, a significant reduction of ILC3s from Csf2 -/donors was observed at a level similar to ILC3s from the wild-type donors, suggesting paracrine GM-CSF induced by α-DR3 is sufficient to induce loss of Csf2 -/-ILC3s (Fig. 2j ). In align with this scenario, systemic overexpression of GM-CSF by hydrodynamic injection also resulted in loss of ILC3s in the large intestine ( Fig. 2k ).
In the Rag2 -/-Il2rg -/recipients that were reconstituted with Csf2 -/bone marrow cells, no significant loss of ILC3s was induced by α-DR3, although a trend to a decrease was observed, probably due to few GM-CSF-sufficient ILC3s developmentally independent of the common gamma chain in the intestine ( Fig. 2m-o) . The above phenomenon confirms that hematopoietic cell-derived GM-CSF triggered by α-DR3 signaling is required for ILC3 loss. Supplementation of Csf2 -/bone marrow cells with Rag1 -/-Rorc gfp/gfp bone marrow cells resulted in dramatic loss of ILC3s from Csf2 -/donors in response to α-DR3 ( Fig. 2m, n) . This suggests that innate non-ILC3 sources of GM-CSF from the hematopoietic compartment triggered by α-DR3 could induce reduction of ILC3s in the intestine. In summary, α-DR3-induced GM-CSF from both ILC3s and non-ILC3s collectively drive the loss of ILC3s.
IL-23 is important for α-DR3-induced loss of ILC3s. Receptor for GM-CSF is typically expressed by myeloid cells but not ILC3s, so elimination of ILC3s by GM-CSF may be indirect. Indeed, we found that the mRNA expression of both Csf2ra and Csfr2b was much lower in ILC3s than in the CD11b + myeloid cells ( Fig. 3a , b), and Csf2rb was not detected on ILC3s (Fig. 3a, b) . A previous study suggests that IL-23, which could be produced by macrophage or dendritic cells, is important for pathology of α-CD40induced colitis, in which ILC3 loss occurs 26 . We found that the mRNA expression of Il23a and Il12b, genes encoding two subunits of IL-23, was enhanced upon α-DR3 treatment (Fig. 3c ). When we neutralized p40, a shared subunit by IL-23 and IL-12, loss of ILC3s driven by α-DR3 was significantly blocked ( Fig. 3d-f ). Consistently, blockade of IL-23 with α-p19, but not blockade of IL-12 with α-p75 neutralizing antibodies, reversed loss of ILC3s induced by α-DR3, as indicated by percentages and absolute numbers of ILC3s ( Fig. 3g -j). To further investigate the effect of IL-23 or IL-12 on loss of ILC3s, we overexpressed IL-23 or IL-12 in vivo through hydrodynamic injection. Consistently, forced expression of IL-23 but not IL-12 led to a dramatic reduction of ILC3s in the large intestine ( Fig. 3k, l ), suggesting a key role for IL-23 in α-DR3-driven ILC3 loss.
The above findings showed that both GM-CSF and p40 were required for α-DR3-induced ILC3 loss (Figs. 2g, h, 3e, f), and that overexpression of either GM-CSF or IL-23 alone could cause reduction of ILC3s (Figs. 2k, 3k, l). However, GM-CSF overexpression failed to induce ILC3 loss when p40 was blocked ( Fig. 3m ). Conversely, IL-23 overexpression caused comparably profound loss of ILC3s in Csf2 +/and Csf2 -/mice ( Fig. 3n, o ). This suggests that overexpression of IL-23 could induce loss of ILC3s in a GM-CSF-independent mechanism.
Upregulation of IL-23 by α-DR3 is dependent on GM-CSF. Upon α-DR3 treatment, loss of ILC3s was found to be accompanied by infiltration of CD11b + myeloid cells ( Fig. 4a-d ). In wild-type mice, the total numbers and percentages of CD11b + CD11c + cells and eosinophils (CD11b + CD11c -Siglec-F + ) in live cells were dramatically enhanced ( Fig. 4a, b ; Supplementary  Fig. 3 ). In Rag1 -/mice, the numbers of CD11b + CD11c + cells, eosinophils, and neutrophils (CD11b + CD11c -Ly6G + ) were all increased upon α-DR3 treatment ( Fig. 4c ; Supplementary Fig. 3 ). Strikingly, blockade of GM-CSF suppressed the infiltration of CD11b + CD11c + cells, eosinophils, and neutrophils in Rag1 -/mice as indicated by the decreased proportion of these cells among live cells ( Fig. 4d; Supplementary Fig. 3 ). In addition, induction of Il23a and Il12b mRNA expression in large intestinal LPLs was significantly suppressed when GM-CSF was neutralized ( Fig. 4e ). We further purified different subsets of cells that have been reported to be sources of IL-23 in the intestine Fig. 2 Autocrine and paracrine GM-CSF induced by α-DR3 is critical for ILC3 loss. Rorc gfp/+ (a), Rag1 -/-Rorc gfp/+ (b), or Rag1 -/-Rorc-creRosa26 stop-YFP mice (c) were treated with α-DR3, and large intestinal LPLs were analyzed 4 days later. a-c Expression of Ki67, Lin, RORγt, and YFP was analyzed. a, b Percentages of Ki67 + cells in ILC3s are shown. c Percentages of Lin -YFP + RORγtand Lin -YFP + RORγt + cells in Lincells are shown. d, e Rag1 -/mice were treated with α-DR3 antibody, and large intestinal LPLs were isolated for analysis 24 h later. f-h Mice were treated with α-DR3 with (α-DR3+α-GM-CSF) or without (α-DR3+IgG) injection of neutralization antibody for GM-CSF. i, j, l-n Rag2 -/-Il2rg -/mice were half-lethally irradiated and transferred with Thy1.1 + wild-type bone marrow (BM) and Thy1.2 + Csf2 -/-BM mixed at 1:1 ratio (i, j), Csf2 -/-BM, or Csf2 -/-BM and Rag1 -/-Rorc gfp/gfp BM mixed at 1:1 ratio (l-n). i, l Protocols for bone marrow transfer. k Rag1 -/mice were treated with 10 µg of GM-CSF or control plasmid DNA through hydrodynamic injection, and large intestinal LPLs were isolated for analysis 4 Supplementary Fig. 4A) 23, 24, [42] [43] [44] . Real-time RT-PCR analysis revealed that CD11b + CD11c + CD103cells, which include previously described sources of IL-1β/IL-23/TL1A 23, 24, 42 , were predominantly enriched for both Il23a and Il12b mRNA expression ( Fig. 4f; Supplementary Fig. 4A ). Notably, CD11b + CD11c + CD103cells but no other analyzed types of cells showed increased Il23a and Il12b mRNA expression in α-DR3-treated group than control ( Fig. 4f; Supplementary Fig. 4A ). Although a previous study suggested a direct role for GM-CSF in enhancing the mRNA expression of IL-23 45 , GM-CSF had no observed effect on Il23a and Il12b mRNA expression in purified CD11b + CD11c + CD103cells in vitro ( Fig. 4g; Supplementary Fig. 4A ). Together, these data indicate that α-DR3 leads to enhanced IL-23 expression in the intestine by accumulation of CD11b + IL-23-producing myeloid cells through GM-CSF. A previous study has shown that IL-23 promotes GM-CSF production from ILC3s 26 . Since both IL-23 and GM-CSF were upregulated by α-DR3 treatment (Figs. 2d,  3c) , it is likely that IL-23 and GM-CSF collaboratively drive the loss of ILC3s in an autocrine loop during α-DR3-induced inflammation.
α-DR3 stimulates GM-CSF production from ILC3s through p38. To determine the effect of α-DR3 on ILC3s at a genome-wide scale, we purified ILC3s from α-DR3 or PBS-treated Rorc gfp/+ Rag1 -/mice and performed transcriptome sequencing. Total of 515 and 609 genes were found to be upregulated and downregulated, respectively, for more than 1.5-fold in ILC3s from α-DR3-treated mice compared with the control group (Supplementary Data 1 and Supplementary Fig. 4B ). Gene ontology enrichment analysis of upregulated targets in the α-DR3 treatment ARTICLE group revealed overrepresentation of biological processes, including cytokine mediated signaling pathway, cellular defense response, locomotion, and MAPK cascade ( Fig. 5a ; Supplementary  Figs. 4B, 5A ). The downregulated genes were enriched in phospholipid metabolic process, DNA repair, and biosynthetic processes ( Fig. 5a; Supplementary Fig. 4B ). We also manually categorized a series of downregulated genes functionally related to immune regulation ( Supplementary Figs. 4B, 5B) . Notably, confirmation of the downregulated expression of RORgt and upregulated expression of Tnfsf4 in ILC3s from α-DR3-treated mice by real-time RT-PCR was consistent with a previously reported role for TL1A on splenic Lti cells in vitro (Fig. 5b) 46 . Cytokines upregulated in ILC3s of α-DR3-treated mice, including Ltb and Il22, indicated enhanced function of ILC3s to recruit neutrophils ( Fig. 5b) 47, 48 . A group of upregulated genes belonging to gene category of locomotion, consisting of chemokine receptors, Rho GTPase, and growth factors, suggested modulation of cell migration activity by DR3 signaling (Supplementary Figs. 4B, 5A , 5C) 49 . The upregulation of Ccr7 together with the downregulation of Ccr9 and Itgb7 reflected a suppression of the retention of α-DR3-treated ILC3s in the gut ( Supplementary Fig. 5C ) 50, 51 . However, the differential expression of CCR7 protein in ILC3s in α-DR3-treated mice was inconsistent with the change at mRNA level ( Supplementary Fig. 5D ). We observed no accumulation of ILC3s in other organs, including the small intestine, mesenteric lymph nodes, spleen, peritoneal cavity, or blood, suggesting ILC3s did not preferentially or specifically translocate to one of the above places ( Supplementary Fig. 5E, F) . Interestingly, upregulated genes in the cellular defense response group contained a cluster of members encoding MHCII ( Supplementary Figs. 4B, 5A) 52, 53 . Flow-cytometric analysis confirmed the enhanced expression of MHCII at the protein level in ILC3s of α-DR3-treated mice ( Supplementary Fig. 5G, H) . We also found that the mRNA expression of Zfp36 and Zfp36l1, tristetraprolin molecules playing regulatory roles in inflammation, was decreased in ILC3s of α-DR3-treated mice (Fig. 5b) 54 .
In accordance with upregulation of Ccr6 mRNA expression in ILC3s upon α-DR3 treatment, we observed a trend toward a proportional increase of CCR6 + NKp46 -ILC3s and a trend toward a decrease of NCR + ILC3s and CCR6 -NKp46 -ILC3s among the total ILC3s ( Supplementary Fig. 6A, B) . But the absolute numbers of all subsets of ILC3s were reduced ( Supplementary Fig. 6C) . Notably, the upregulation of MHCII expression was mainly on NCR + ILC3s and CCR6 -NKp46 -ILC3s ( Supplementary Fig. 6D ), whereas the upregulation of IL-22 expression was mainly on NCR + ILC3s and CCR6 + NKp46 -ILC3s ( Supplementary Fig. 6E ). Enhancement of OX40L expression was found on all subsets of ILC3s upon treatment of α-DR3 ( Supplementary Fig. 6F ).
The upregulation of several MAPK cascade genes implied activation of MAPK signaling, which was consistent with previously reported downstream signaling of DR3 through MAPK ( Supplementary Figs. 4B, 5A) 55 . We have confirmed by real-time RT-PCR that the expression Map2k3 and Traf1 was significantly upregulated when purified ILC3s were treated with α-DR3 in vitro ( Fig. 5c; Supplementary Fig. 4C ). We then investigated if GM-CSF expression, which was a key event for inflammatory storm driven by α-DR3, was regulated by the MAPK pathway. Using a series of small molecule inhibitors, we found that inhibitors of p38 (SB203580), but not NF-κB (Bay11-7082), JNK (SP600125), or ERK (SCH772984), dramatically suppressed α-DR3-induced GM-CSF expression in ILC3s induced by α-DR3 (Fig. 5d, e ). TL1A-induced GM-CSF expression by ILC3s was similarly inhibited by SB203580 (Fig. 5f ). Importantly, TL1A-induced GM-CSF in human tonsil ILC3s was also suppressed by SB203580, suggesting a conserved regulation of GM-CSF by p38 in mice and humans (Fig. 5g ). Consistent with this observation, an increased level of phosphorylated p38 was observed in ILC3s within 1 h of α-DR3 treatment (Fig. 5h, i) . SB203580 had no cytotoxic effects on human or mouse ILC3s, as indicated by the comparable percentages of live lymphocytes, similar number of ILC3s and no reduction of proportions of ILC3s among lymphocytes in SB203580-treated groups compared with control groups (Supplementary Fig. 7) . Therefore, the suppression of GM-CSF expression in ILC3s by SB203580 was not due to cytotoxicity. The above data suggest that α-DR3 signals through the p38 pathway to induce the expression of GM-CSF by ILC3s.
DR3-Fc treatment ameliorates α-CD40-induced colitis. During α-CD40-induced colitis, the mRNA expression of TL1A was significantly elevated (Fig. 6a) . To evaluate the role of TL1A/ DR3 signaling in α-CD40-induced intestinal pathology, we neutralized TL1A by treating mice with DR3-Fc, a synthesized decoy receptor for TL1A by expression of DR3 conjugated with mouse-Fc ( Fig. 6b-j) . We found that the DR3-Fc-treated mice lost less body weight and recovered sooner than vehicle or IgGtreated group in α-CD40-induced colitis (Fig. 6b) . Moreover, colon length in DR3-Fc-treated group was longer (Fig. 6c, d) .
Percentages of neutrophils in the LPLs were decreased in DR3-Fc-treated mice (Fig. 6e ). Histological analysis using hematoxylin and eosin (H&E) staining showed less severe inflammation in DR3-Fc-treated mice (Fig. 6f, g) . Consistent with the function of α-DR3 in promoting GM-CSF expression by ILC3s, we observed reduced GM-CSF expression by ILC3s in DR3-Fctreated mice 24 h after α-CD40 injection (Fig. 6h) . The above data indicate a pathogenic role for TL1A in α-CD40-induced colitis.
Loss of ILC3s has been reported in α-CD40-induced colitis in previous study 26 . We found that blockade of TL1A by DR3-Fc significantly restored the cell numbers and percentages of ILC3s in lymphocytes compared with control ( Fig. 6i, j) , whereas no effect of DR3-Fc on percentages and numbers of ILC3s was observed under the steady state ( Supplementary Fig. 8A, B) . These results suggest an essential role for TL1A/DR3 signaling in ILC3 loss during innate colitis.
α-DR3 exacerbates innate colitis in an ILC3-dependent manner. A previous study showed that blockade of TL1A ameliorated chronic DSS-induced colitis by suppression of Th1 and Th17 responses in wild-type mice 19 . In DSS-induced colitis in Rag1 -/mice, we found that DR3-Fc-treated mice lost less weight and had increased colon length ( Fig. 7a, b ; Supplementary Fig. 8C ). The total numbers of neutrophils were less in DR3-Fc-treated mice (Fig. 7c ). This suggests that TL1A/DR3 signaling is pathogenic in DSS-induced colitis in the absence of the adaptive immune system. Consistent with the protective effect of DR3-Fc in colitis, α-DR3-exacerbated DSS-induced colitis in wild-type mice manifested by more rapid rate of weight loss, despite a promotive effect on immune-suppressive Tregs ( Fig. 7d; Supplementary Fig. 8D ). In DSS-induced colitis, α-DR3-treated mice showed shorter colon lengths ( Fig. 7e; Supplementary Fig. 8E ), enhanced numbers of neutrophils and eosinophils (Fig. 7f) , and exacerbated intestinal pathology characterized by damage to the epithelial cells and infiltration of leukocytes than control group (Fig. 7g ; Supplementary Fig. 8F ). In Rag1 -/mice, α-DR3 treatment similarly caused a more rapid rate of weight loss (Fig. 7i ), shorter colons ( Fig. 7j; Supplementary Fig. 8G ), increased number of neutrophils and eosinophils in lamina propria (Fig. 7k) , as well as more severe intestinal pathology during DSS-induced colitis compared with controls ( Fig. 7l; Supplementary Fig. 8H ). Furthermore, in both wild-type and Rag1 -/mice, the exacerbation of colitis in α-DR3treated group was accompanied by loss of ILC3s (Fig. 7h, m) . Therefore, α-DR3-exacerbated DSS-induced colitis independently of the adaptive immune system.
Previous studies have shown that enhanced TL1A/ DR3 signaling results in small intestinal inflammation by promoting the function of ILC2s 3, 18 . To delineate the role of ILC3s in TL1A/DR3-induced inflammation, we administered α-DR3 and induced DSS colitis in littermate Rag1 -/-Rorc gfp/+ and Rag1 -/-Rorc gfp/gfp mice. The latter lacked ILC3s. Without α-DR3 treatment, Rag1 -/-Rorc gfp/+ and Rag1 -/-Rorc gfp/gfp mice exhibited similar percentages of weight loss (Fig. 7n ), colon length ( Fig. 7o ; Supplementary Fig. 8I ), and intestinal pathology as indicated by the infiltration of neutrophils/eosinophils and histological changes in the colon tissues ( Fig. 7p, q; Supplementary Fig. 8J ). However, α-DR3 exacerbated the colitis indicated by above indexes in Rag1 -/-Rorc gfp/+ , but not in Rag1 -/-Rorc gfp/gfp mice, suggesting ILC3s are required for the pathogenic effect of α-DR3 in DSS-induced innate colitis ( Fig. 7n-q; Supplementary Fig. 8I , J). Loss of ILC3s was observed in Rag1 -/-Rorc gfp/+ mice upon α-DR3 treatment ( Supplementary Fig. 8K ). However, the activation of ILC3s by α-DR3 signaling at an early phase may serve as a prerequisite for exacerbation of colitis by α-DR3. We therefore conclude ILC3s are indispensable for α-DR3-exacerbated DSSinduced colitis in Rag1 -/mice. 1, 3 . The activation of DR3 signaling by an agonistic antibody has been proved to be effective in alleviating GVHD and lung allergy in mouse models by promoting Tregs 6, [8] [9] [10] . The activation of DR3 signaling has also been indicated to be applied in immuno-cancer therapy by facilitating the CD8 + T-cell responses 56 .
Discussion

DR3 exhibits broad expression profile among lymphocytes and regulates inflammation in dual directions
However, TL1A/DR3 signaling is considered to play a pathogenic role in IBD through various mechanisms, which brings forward a high risk for the exacerbation of intestinal inflammation by activation of DR3 signaling 12 . In this study, we have found that activation of DR3 signaling leads to exacerbation of the colitis through targeting ILC3s, which were finally eliminated from the intestine through GM-CSF/IL-23-dependent mechanism. In wild-type mice, targets for α-DR3 are broad and include subsets of CD4 + T effector cells, CD8 + T cells, and ILCs 1,3 , and the exacerbating effect of α-DR3 may be a reflection of multifaceted immune responses influenced by DR3 signaling. In Rag1 -/mice, targets for DR3 are more limited, and this model provided us a simpler system to delineate the impact of α-DR3 on ILC3s.
A previous study showed that TL1A or DR3-deficient mice were susceptible to DSS-induced colitis due to impaired maintenance of Tregs 11 . In addition, a recent study reported that mice with genetic deletion of DR3 specifically on ILC3s were more susceptible to DSSinduced colitis, mainly due to decreased IL-22 from ILC3s 57 . Our data, together with a previous report, suggest that TL1A/ DR3 signaling plays a pathogenic role in DSS-induced colitis 19 . The discrepancies among the above findings on the role of DR3 in innate colitis may be due to differential experimental settings using geneticdeficient mice compared with transient blockade of DR3 signaling using TL1A neutralization antibody or DR3-Fc. Genetic deficiency of TL1A or DR3 could be considered as a long-term prevention protocol for colitis, which could not be completely represented with antibody blockade. It is possible that in mice with genetic deficiency of DR3 on ILC3s, constantly suboptimal level of IL-22 from birth makes the individual more susceptible to exacerbated colitis led by lack of IL-22. Whereas in antibody treatment experiments, blockade of TL1A or DR3 started after onset of DSS-induced colitis, before which no possibly impaired epithelial integrity due to lack of IL-22 occurred. Therefore, blockade of TL1A/DR3 using antibodies resulted in ameliorated colitis likely by suppressing the pathogenicity of ILC3s. In the future, it will be necessary to test whether a prevention protocol by long-term blockade of TL1A/DR3 using antibodies would increase the susceptibility to intestinal inflammation. We have demonstrated that α-DR3 treatment results in the accumulation of IL-23-producing myeloid cells through GM-CSF and promotes the function of CD11b + CD11c + CD103cells to express IL-23 at the mRNA level. A previous study has shown that GM-CSF production from ILC3s can be enhanced by IL-23 26 . It is possible that DR3 signaling works in synergy with IL-23 to induce GM-CSF production from ILC3s, generating a positive feedback loop for the progression of inflammation. Furthermore, CD11c + MHCII high myeloid cells have been found to localize closely with ILC3s in cryptopatches or lymphoid follicles during colitis, which may allow for prompt crosstalk between the two 26, 33 . Except for GM-CSF, IL-23 could also enhance the production of IL-17, IL-22, and IFN-γ from ILC3s, which further facilitate the recruitment of proinflammatory myeloid cells 58 . Therefore, although GM-CSF could be from other sources, on the basis that they are IL-23Rexpressing cells and neighbors of IL-23-producing cells, ILC3s appeared to be an irreplaceable effector population in α-DR3exacerbated innate colitis.
We have shown that IL-23 induces loss of ILC3s from the intestine even in the absence of GM-CSF. Consistent with this observation, another study found that IL-23 administration caused loss of ILC3s from the small intestine 59 . The reduction of proportion of IL-22-producing ILC3s is phenotypically in accordance with the situation in CD patients 27, 28 . IL-23-driven loss of ILC3s may be a critical though not unique mechanism for this phenomenon. The correlations among TL1A, GM-CSF, IL-23 expression, and reduction of IL-22-producing ILC3s in patients with IBD needs to be further investigated. Interestingly, a recent study demonstrated that IL-23 mediates the expulsion of T, B, and NK cells in the mouse model of lung tumor 60 . Therefore, IL-23 may directly or indirectly orchestrate profiles of chemotaxis in local environment and result in reorganization of the composition of immune cells. Further understanding the molecular mechanism underlying exclusion of immune cells by IL-23 will provide insights into pathogenesis of IBD and tumors.
We demonstrated that loss of ILC3s induced by α-DR3 is less likely due to apoptosis or fate conversion in situ. It is possible that ILC3s undergo other forms of cell death independently of caspase 3 such as necroptosis 61 . Mice with genetic deficiency for key signaling molecules controlling other forms of cell death will help to test this possibility. Search for ILC3s in multiple tissues failed to locate accumulation of ILC3s in the small intestine, mesenteric lymph nodes, spleen, peritoneal cavity, or blood. Although fate conversion of ILC3s was not found in situ, it is also possible that ILC3s first migrate to other organs and then fate conversion of ILC3s takes place. A thorough spatial-temporal inspection for ILC3s locally and in various organs, especially with the facilitation of Kaede mouse and intravital microscopy, is required for further elucidation of the mechanisms for loss of ILC3s 62, 63 .
A previous study suggests that mobilization of ILC3s out of the cryptopatches may play a role in coordination and perpetuation of the inflammation in the gut 26 . However, final reduction of ILC3s can result in contraction of the inflammation, which works as an efficient feedback mechanism to control overt inflammatory responses. The strategies we used for blocking loss of ILC3s using α-GM-CSF, α-p19, α-p40, or DR3-Fc in this study may also simultaneously ameliorate colitis by limiting the pathogenicity of ILC3s or other mechanisms 26, 64 . This makes it difficult for us to assess the consequence of loss of ILC3s per se, without affecting cytokine production of ILC3s. One would suspect abnormal retention of pro-inflammatory ILC3s would lead to persistent inflammation and severe tissue damage, which would be important to investigate in the future.
Methods
Mice. Wild-type mice were purchased from Shanghai SLAC Laboratory Animal Co. Rag1 -/-, Csf2 −/− , Rorc gfp/gfp , Rorc-cre, Rosa26 stop-YFP , and Thy1.1 mice were purchased from Jackson laboratory. Rag2 −/− Il2rg −/− mice were purchased from Taconic Biosciences. Mice used for in vivo studies were littermate controlled and were 6-10 weeks old. Both male and female mice were used unless otherwise noted. All mice used in this study are on C57BL/6 background, and were maintained in specific pathogen-free conditions. In DSS-induced colitis, α-CD40-induced colitis and other in vivo experiments, littermate mice were co-housed since weaning and randomly separated into control and treatment groups to avoid variation in distribution of microflora. All mice were fed with a plain commercial diet (Silaikang, Shanghai). Mice were housed in corn-cob-bedding cages in a room with the light-dark cycle (lights on at 6:00 and off at 18:00). All animal experiments were performed in compliance with the guide for the care and use of laboratory animals, and were approved by the institutional biomedical research ethics committee of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
In vivo treatment of mice with antibodies. Mice on a wild-type or Rag1 -/background were i.p. injected with agonistic antibody against DR3 (4C12, Biolegend) at 2.5 µg and 1 µg, respectively, every 2 days. Control mice were injected with same amount of Isotype Hamster IgG (Biolegend) or PBS. Unless otherwise noted, mice were killed for analysis 4 days after the first injection. For some experiments, rat IgG (Sangon Biotech) or neutralization antibodies targeting GM-CSF (MP1-22E9, Bioxcel), p40 (C17.8, Bioxcel), p19 (G23-8, Thermo Fisher Scientific), and p75 (R2-9A5, Bioxcel) were injected at a dose of 250 µg on day 0 and day 2. Mice were killed for analysis on day 4 upon α-DR3 treatment. Same protocol of blocking antibody treatment was performed on day 0 and day 2 of hydrodynamic injection experiments.
Hydrodynamic gene delivery. Control vector (pRK) and pRK-IL-23 have been previously described. pRK-GM-CSF and pRK-TL1A were generated by cloning the coding sequence of mouse GM-CSF and TL1A to pRK vector, respectively. Generation of pRK-IL-12 was performed according to previously published method 65 : coding sequence of Il12b (the stop codon was deleted) and Il12a (the first 22 amino acids were deleted) was linked by a (Gly 4 Ser 3 ) 3 linker and cloned to the pRK vector. Plasmid DNA was introduced into mice using a hydrodynamic tail vein injection. Briefly, 10 µg of DNA/mouse was diluted in 1.5 to 2.0 ml of TransIT-EE Hydrodynamic Delivery Solution (Mirus) at 0.1 ml/g body weight. The DNA solution was injected into mice through the tail vein using a 27-gauge needle within a time period of 5 to 10 s. Hydrodynamic injection was performed only once, and mice were killed 4 days after injection.
Bone marrow transfer. Rag2 −/− Il2rg −/− mice were irradiated at 550 rads once, and immediately transferred with 5 × 10 6 donor bone marrow cells. Chimeric mice were used for further experiments 6 weeks after transfer.
Isolation of intestinal LPLs and intestinal epithelial cells. Small or large intestines were dissected, fat tissues and peyer's patches were removed. Intestines were cut open longitudinally and washed in PBS. Intestines were then cut into 3cm-long pieces, washed, and shaken in PBS containing 1 mM DTT for 10 min at RT. Intestines were incubated with shaking in PBS containing 30 mM EDTA and 10 mM HEPES at 37°C for 10 min for two cycles. Supernatant from the first round of EDTA was saved as intestinal epithelial cells. The tissues were then digested in the RPMI1640 medium (Thermo Fisher Scientific) containing DNase I (150 µg/ml, Sigma) and collagenase VIII (200 U/ml, Sigma) at 37°C in a 5% CO 2 incubator for 1.5 h. The digested tissues were homogenized by vigorous shaking and passed through 100-µm cell strainer. Mononuclear cells were then harvested from the interphase of an 80 and 40% Percoll gradient after a spin at 2500 rpm for 20 min at RT.
Cell suspension preparation from different tissues. Peritoneal lavage cells were isolated by flushing the peritoneal cavity with 10 ml of PBS. Cell suspensions were prepared from the spleen, and mesenteric lymph nodes by gentle mechanical disruption and passed through a 50-µm nylon mesh. Blood was collected by the heart punctures. Mononuclear cells from the blood were isolated from interface of Ficoll-Paque density-gradient centrifugation at 2500 rpm for 20 min at RT.
Flow cytometry. Anti-mouse CD16/32 antibody was used to block the nonspecific binding to Fc receptors before all surface stainings. Dead cells were stained with live and dead violet viability kit (Invitrogen), and were gated out in analysis. Antibodies used for regular flow cytometry are listed in Supplementary Table 1 . α-p-p38 was from Cell signaling Technology. For nuclear stainings, cells were fixed and permeabilized using a Mouse Regulatory T Cell Staining Kit (Thermo Fisher Scientific). BD Cytofix/Cytoperm™ kit was used for detection of GM-CSF production. In brief, cells were stimulated by PMA (50 ng/ml, Sigma) and ionomycin (500 ng/ml, Sigma) for 4 h, except for experiments using compound inhibitors in Fig. 5 and S5 , where PMA and ionomycin stimulation were not used. Brefeldin A (2 µg/ml, Sigma) was added for the last 2 h before cells were harvested for analysis. For detection of p-p38, cells were first fixed with the BD Cytofix kit and permeablized with 100% methanol followed by
